🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07370519
Recruiting Phase 2

Topical Application of Lactobacillus Reuteri for Androgenetic Alopecia

NCT07370519 · tracked via the Priya Life Science China tracker
Sponsor
Shenzhen People's Hospital
Phase
Phase 2
Started
2026-01-25
Last updated
2026-04-01

Condition(s) studied

Androgenetic Alopecia (AGA)

Investigational drug(s) / intervention(s)

Lactobacillus reuteriInactivated Lactobacillus reuteri5% MinoxidilNormal Saline

Lactobacillus reuteri: Daily application of 1 sachet containing Lactobacillus reuteri powder (≈10\^9 CFU) dissolved in 1 mL normal saline within a brown glass vial. After thorough mixing, 1 mL of the probiotic solution was topically applied to the scalp using cotton swabs following scalp cleansing. Participants refrained from hair washing for ≥6 hours post-application. Applied once daily for 12 months.

Inactivated Lactobacillus reuteri: Daily application of 1 sachet containing inactivated Lactobacillus reuteri powder (≈10\^9 CFU pre-inactivation) dissolved in 1 mL normal saline within a brown glass vial. After thorough mixing, 1 mL of the solution was topically applied to the scalp using cotton swabs following scalp cleansing. Participants refrained from hair washing for ≥6 hours post-application. Applied once daily for 12 months.

5% Minoxidil: Commercially available 5% minoxidil was aliquoted into brown glass vials (1 mL/vial). Following daily scalp cleansing, 1 mL solution was topically applied to the scalp. Participants refrained from hair washing for ≥6 hours post-application. Applied once daily for 12 months.

Normal Saline: Normal saline was aliquoted into brown glass vials (1 mL/vial). Following daily scalp cleansing, 1 mL solution was topically applied to the scalp using cotton swabs. Participants refrained from hair washing for ≥6 hours post-application. Applied once daily for 12 months.

Study summary

This is a single-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate whether topical application of Lactobacillus reuteri can safely and effectively treat androgenetic alopecia. The study is based on the concept that balancing the scalp's microbial community may support hair follicle function. Participants will be randomly assigned to one of four groups receiving either active probiotic solution, inactivated probiotic solution (control for non-viable bacterial effects), a saline placebo, or the standard treatment 5% minoxidil solution for 12 months. Neither participants nor assessing clinicians will know the assigned treatment. The main goal is to measure improvement in hair count per square centimeter after one year. Additional measures include changes in hair thickness and quality. This research seeks to provide high-quality scientific evidence on a new microbiome-targeting approach, offering future patients and healthcare providers insights into a potential alternative or complementary treatment strategy for hair loss.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: 1. Patients meeting AGA diagnostic criteria (confirmed by medical history, clinical presentation, and trichoscopy) classified as Norwood-Hamilton stage II-IV or Ludwig grade I-III; 2. Provision of informed consent and voluntary participation; 3. Aged 18-60 years with generally good health status; 4. No use of any hair loss medications within the past six months; 5. Absence of alopecia areata, local infections, or neuromuscular disorders. Exclusion Criteria: 1. AGA progression \>5 years; 2. Active skin disease (e.g., psoriasis flare) or uncontrolled diabetes/CVD; 3. Investigator-assessed protocol non-feasibility.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Shenzhen People's Hospital Shenzhen Guangdong Recruiting

More Shenzhen People's Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07370519 on ClinicalTrials.gov ↗ ← All trials in China